MicroRNA-495 Inhibits chondrogenic differentiation in human mesenchymal stem cells by targeting Sox9

Stem Cells and Development

Volumn 23, Issue 15, 2014, Pages 1798-1808

  Lee, Seulgi ^a,b   Yoon, Dong Suk ^a,b   Paik, Seungil ^a   Lee, Kyoung Mi ^a,b   Jang, Yeonsue ^a   Lee, Jin Woo ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; COLLAGEN TYPE 2; LUCIFERASE; MICRORNA; MICRORNA 495; PROTEOGLYCAN; TRANSCRIPTION FACTOR SOX9; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; BIOLOGICAL MARKER; GLYCOSAMINOGLYCAN; MESSENGER RNA; MIRN495 MICRORNA, HUMAN; PROTEIN BINDING; SOX9 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ADULT; ARTICLE; BINDING SITE; CELL DIFFERENTIATION; CHONDROGENESIS; CHONDROSARCOMA CELL LINE; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR MATRIX; FEMALE; GENE OVEREXPRESSION; GENE REPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MESENCHYMAL STEM CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN BINDING; REAL TIME POLYMERASE CHAIN REACTION; CELL CULTURE; CELL LINEAGE; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STROMA CELL; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE; YOUNG ADULT;

3' UNTRANSLATED REGIONS; ADULT; BASE SEQUENCE; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL LINEAGE; CELLS, CULTURED; CHONDROGENESIS; GENE EXPRESSION REGULATION; GLYCOSAMINOGLYCANS; HUMANS; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STROMAL CELLS; MICRORNAS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEOGLYCANS; RNA, MESSENGER; SOX9 TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA3; YOUNG ADULT;

EID: 84904632601     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2013.0609     Document Type: Article

References (43)

1. DeLise AM, L Fischer and RS Tuan. (2000). Cellular interactions and signaling in cartilage development. Osteoarthritis Cartilage 8:309-334.
2. Goldring MB, K Tsuchimochi and K Ijiri. (2006). The control of chondrogenesis. J Cell Biochem 97:33-44.
3. Lefebvre V, S Garofalo and B de Crombrugghe. (1995). Type X collagen gene expression in mouse chondrocytes immortalized by a temperature-sensitive simian virus 40 large tumor antigen. J Cell Biol 128:239-245.
4. Seyedin SM, AY Thompson, H Bentz, DM Rosen, JM McPherson, A Conti, NR Siegel, GR Galluppi and KA Piez. (1986). Cartilage-inducing factor-A. Apparent identity to transforming growth factor-beta. J Biol Chem 261:5693-5695.
5. Seyedin SM, PR Segarini, DM Rosen, AY Thompson, H Bentz and J Graycar. (1987). Cartilage-inducing factor-B is a unique protein structurally and functionally related to transforming growth factor-beta. J Biol Chem 262:1946-1949.
6. Furumatsu T, M Tsuda, K Yoshida, N Taniguchi, T Ito, M Hashimoto, T Ito and H Asahara. (2005). Sox9 and p300 cooperatively regulate chromatin-mediated transcription. J Biol Chem 280:35203-35208.
7. Zou H, R Wieser, J Massague and L Niswander. (1997). Distinct roles of type I bone morphogenetic protein receptors in the formation and differentiation of cartilage. Genes Dev 11:2191-2203.
8. Grunder T, C Gaissmaier, J Fritz, R Stoop, P Hortschansky, J Mollenhauer and WK Aicher. (2004). Bone morphogenetic protein (BMP)-2 enhances the expression of type II collagen and aggrecan in chondrocytes embedded in alginate beads. Osteoarthritis Cartilage 12:559-567.
9. Brady K, SC Dickinson, PV Guillot, J Polak, AW Blom, W Kafienah and AP Hollander. (2013). Human fetal and adult bone marrow-derived mesenchymal stem cells use different signaling pathways for the initiation of chondrogenesis. Stem Cells Dev 23:541-554.
10. Akiyama H. (2008). Control of chondrogenesis by the transcription factor Sox9. Mod Rheumatol 18:213-219.
11. Akiyama H, MC Chaboissier, JF Martin, A Schedl and B de Crombrugghe. (2002). The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev 16:2813-2828.
12. Bell DM, KK Leung, SC Wheatley, LJ Ng, S Zhou, KW Ling, MH Sham, P Koopman, PP Tam and KS Cheah. (1997). SOX9 directly regulates the type-II collagen gene. Nat Genet 16:174-178.
13. Lefebvre V, W Huang, VR Harley, PN Goodfellow and B de Crombrugghe. (1997). SOX9 is a potent activator of the chondrocyte-specific enhancer of the pro alpha1(II) collagen gene. Mol Cell Biol 17:2336-2346.
14. Bridgewater LC, V Lefebvre and B de Crombrugghe. (1998). Chondrocyte-specific enhancer elements in the Col11a2 gene resemble the Col2a1 tissue-specific enhancer. J Biol Chem 273:14998-15006.
15. Sekiya I, K Tsuji, P Koopman, H Watanabe, Y Yamada, K Shinomiya, A Nifuji and M Noda. (2000). SOX9 enhances aggrecan gene promoter/enhancer activity and is up-regulated by retinoic acid in a cartilage-derived cell line, TC6. J Biol Chem 275:10738-10744.
16. Xie WF, X Zhang, S Sakano, V Lefebvre and LJ Sandell. (1999). Trans-activation of the mouse cartilage-derived retinoic acid-sensitive protein gene by Sox9. J Bone Miner Res 14:757-763.
17. Cheng AM, MW Byrom, J Shelton and LP Ford. (2005). Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 33:1290-1297.
18. Chen CZ, L Li, HF Lodish and DP Bartel. (2004). Micro-RNAs modulate hematopoietic lineage differentiation. Science 303:83-86.
19. Bartel DP. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116:281-297.
20. Wienholds E, WP Kloosterman, E Miska, E Alvarez-Saavedra, E Berezikov, E de Bruijn, HR Horvitz, S Kauppinen and RH Plasterk. (2005). MicroRNA expression in zebrafish embryonic development. Science 309:310-311.
21. Tuddenham L, G Wheeler, S Ntounia-Fousara, J Waters, MK Hajihosseini, I Clark and T Dalmay. (2006). The cartilage specific microRNA-140 targets histone deacetylase 4 in mouse cells. FEBS Lett 580:4214-4217.
22. Tardif G, D Hum, JP Pelletier, N Duval and J Martel-Pelletier. (2009). Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic chondrocytes. BMC Musculoskelet Disord 10:148.
23. Miyaki S, T Sato, A Inoue, S Otsuki, Y Ito, S Yokoyama, Y Kato, F Takemoto, T Nakasa, et al. (2010). MicroRNA-140 plays dual roles in both cartilage development and homeostasis. Genes Dev 24:1173-1185.
24. Pais H, FE Nicolas, SM Soond, TE Swingler, IM Clark, A Chantry, V Moulton and T Dalmay. (2010). Analyzing mRNA expression identifies Smad3 as a microRNA-140 target regulated only at protein level. RNA 16:489-494.
25. Nakamura Y, JB Inloes, T Katagiri and T Kobayashi. (2011). Chondrocyte-specific microRNA-140 regulates endochondral bone development and targets Dnpep to modulate bone morphogenetic protein signaling. Mol Cell Biol 31:3019-3028.
26. Lin EA, L Kong, XH Bai, Y Luan and CJ Liu. (2009). miR-199a, a bone morphogenic protein 2-responsive MicroRNA, regulates chondrogenesis via direct targeting to Smad1. J Biol Chem 284:11326-11335.
27. Paik S, HS Jung, S Lee, DS Yoon, MS Park and JW Lee. (2012). miR-449a regulates the chondrogenesis of human mesenchymal stem cells through direct targeting of lymphoid enhancer-binding factor-1. Stem Cells Dev 21:3298-3308.
28. Li Z, Y Cao, Z Jie, Y Liu, Y Li, J Li, G Zhu, Z Liu, Y Tu, et al. (2012). miR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3. Cancer Lett 323:41-47.
29. Jiang X, H Huang, Z Li, C He, Y Li, P Chen, S Gurbuxani, S Arnovitz, GM Hong, et al. (2012). MiR-495 is a tumorsuppressor microRNA down-regulated in MLL-rearranged leukemia. Proc Natl Acad Sci USA 109:19397-19402.
30. Simion A, I Laudadio, PP Prevot, P Raynaud, FP Lemaigre and P Jacquemin. (2010). MiR-495 and miR-218 regulate the expression of the Onecut transcription factors HNF-6 and OC-2. Biochem Biophys Res Commun 391:293-298.
31. Marquardt JU and PR Galle. (2013). Epigenetic regulation of methionine adenosyltransferase 1A; a role for micro RNA based treatment in liver cancer? Hepatology 57:2081-2084.
32. Barry FP, RE Boynton, S Haynesworth, JM Murphy and J Zaia. (1999). The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105). Biochem Biophys Res Commun 265:134-139.
33. Dominici M, K Le Blanc, I Mueller, I Slaper-Cortenbach, F Marini, D Krause, R Deans, A Keating, D Prockop and E Horwitz. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315-317.
34. Conget PA and JJ Minguell. (1999). Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J Cell Physiol 181:67-73.
35. Dai L, X Zhang, X Hu, C Zhou and Y Ao. (2012). Silencing of microRNA-101 prevents IL-1beta-induced extracellular matrix degradation in chondrocytes. Arthritis Res Ther 14:R268.
36. Furumatsu T, M Tsuda, N Taniguchi, Y Tajima and H Asahara. (2005). Smad3 induces chondrogenesis through the activation of SOX9 via CREB-binding protein/p300 recruitment. J Biol Chem 280:8343-8350.
37. Chen SM, HC Chen, SJ Chen, CY Huang, PY Chen, TW Wu, LY Feng, HC Tsai, TN Lui, C Hsueh and KC Wei. (2013). MicroRNA-495 inhibits proliferation of glioblastoma multiforme cells by downregulating cyclin-dependent kinase 6. World J Surg Oncol 11:87.
38. Formosa A, EK Markert, AM Lena, D Italiano, E Finazzi-Agro, AJ Levine, S Bernardini, AV Garabadgiu, G Melino and E Candi. (2013). MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene [Epub ahead of print]; DOI: 10.1038/onc.2013.451.
39. Corsten MF, R Miranda, R Kasmieh, AM Krichevsky, R Weissleder and K Shah. (2007). MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res 67:8994-9000.
40. Babar IA, CJ Cheng, CJ Booth, X Liang, JB Weidhaas, WM Saltzman and FJ Slack. (2012). Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci USA 109:E1695-E1704.
41. van Rooij E, AL Purcell and AA Levin. (2012). Developing microRNA therapeutics. Circ Res 110:496-507.
42. Ibrahim AF, U Weirauch, M Thomas, A Grunweller, RK Hartmann and A Aigner. (2011). Micro RNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 71:5214-5224.
43. Gebert LF, MA Rebhan, SE Crivelli, R Denzler, M Stoffel and J Hall. (2014). Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res 42:609-621.